Antibiotics that inhibit fungal cell wall development

Area of Science:

• Mycology
• Medicinal Chemistry
• Pharmacology

Background:

• The increasing population of immunocompromised patients necessitates the development of novel antifungal agents.
• Current antifungal drugs often target pathways conserved in mammalian cells, leading to toxicity concerns.
• Selective toxicity against fungal cells is a key challenge in antifungal drug discovery.

Purpose of the Study:

• To explore novel antifungal agents with selective toxicity against fungal cells.
• To investigate therapeutic targets within the fungal cell, specifically the cell wall.
• To evaluate the potential of inhibiting fungal cell biosynthesis pathways.

Main Methods:

• Review of existing antifungal agents and their mechanisms of action.
• Identification of fungal-specific targets, including glucan, chitin, and mannan synthesis.
• Analysis of echinocandin lipopeptides, polyoxins, nikkomycins, and pradimicins as potential antifungal candidates.

Main Results:

• Echinocandin lipopeptides (e.g., cilofungin, LY303366) inhibit glucan synthesis and show low toxicity and promising activity.
• Chitin synthase inhibitors (polyoxins, nikkomycins) have limitations due to unfavorable pharmacokinetics.
• Pradimicins selectively bind to mannan, offering a unique antifungal mechanism.

Conclusions:

• Inhibiting fungal cell wall biosynthesis, particularly glucan and mannan pathways, represents a promising strategy for selective antifungal therapy.
• Echinocandins and pradimicins are leading candidates for clinical development due to their efficacy and targeted mechanisms.
• Further research into mannan-binding agents could uncover new therapeutic avenues for fungal infections.